Short-and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya : A Randomized Trial
To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence. Randomized controlled trial. SETTING AND ANALYTIC APPROACH: From September 2003 to November 2004, 234 HIV-infected adults were assigned m-DOT (24 weeks of twice weekly health center...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2008-08, Vol.48 (5), p.611-619 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 619 |
|---|---|
| container_issue | 5 |
| container_start_page | 611 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 48 |
| creator | SARNA, Avina LUCHTERS, Stanley GEIBEL, Scott CHERSICH, Matthew F MUNYAO, Paul KAAI, Susan MANDALIYA, Kishorchandra N SHIKELY, Khadija S TEMMERMAN, Marleen RUTENBERG, Naomi |
| description | To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence.
Randomized controlled trial. SETTING AND ANALYTIC APPROACH: From September 2003 to November 2004, 234 HIV-infected adults were assigned m-DOT (24 weeks of twice weekly health center visits for nurse-observed pill ingestion, adherence support, and medication collection) or standard care. Follow-up continued until week 72. Self-reported and pill-count adherence and, secondarily, viral suppression and body mass index measures are reported. Generalized estimating equations adjusted for intraclient clustering and covariates were used.
During weeks 1-24, 9.1% (9/99) of m-DOT participants reported missing doses compared with 19.1% (20/105) of controls (P = 0.04) and 96.5% (517/571) of m-DOT pill-count measures were >or=95% compared with 86.1% (445/517) in controls [adjusted odds ratio = 4.4; 95% confidence interval (CI) = 2.6 to 7.5; P < 0.001. Adherence with m-DOT was 4.8 times greater (95% CI = 2.7 to 8.6; P < 0.001) with adjustment for depression and HIV-related hospitalization. In weeks 25-48, adherence with m-DOT (488/589) was similar to controls (507/630). Viral suppression at 48 weeks was 2.0 times (95% CI = 0.8 to 5.2; P = 0.13) as likely in m-DOT participants as controls. M-DOT patients had larger body mass index increases at 24 weeks (2.2 vs 1.4 kg/m3; P = 0.014). Viral suppression was more likely at week 48 (21/25 vs 13/22; P = 0.057) and week 72 (27/30 vs 15/23; P = 0.027) among depressed participants receiving m-DOT.
M-DOT increased adherence, most notably among depressed participants. |
| doi_str_mv | 10.1097/QAI.0b013e3181806bf1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69368008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1527719921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-ba433bcfe7957862dca0f7d387b798ba1dc023043a75883339f5cc8a0af519933</originalsourceid><addsrcrecordid>eNqFkV9vFCEUxYnR2D_6DYwhJvbJqZcBZsC3Ta3auKZR1-fJhQGlmYEKs022n16abjTpi0-Qw--cm8sh5AWDUwa6f_t1dXEKBhh3nCmmoDOePSKHTAvR9EqJx_UuW9kIxuUBOSrlCoB1Quin5ICpTkgJ-pDcfv-V8tJgHOk6xZ_NxuWZnnsfLNodTZ5-SWPwwY30fcjOLtOOXpri8k1VVnGp2pLTTcg40U12uMwuLjTEapsNFnxDP7u4Q_qOrui3OiTN4bY6Nzng9Iw88TgV93x_HpMfH843Z5-a9eXHi7PVurGC66UxKDg31rtey1517WgRfD9y1ZteK4NstNByEBx7qRTnXHtprUJAL5nWnB-Tk_vc65x-b11ZhjkU66YJo0vbMnSadwpA_Rds67dL0d4lvnoAXqVtjnWJob52kokOKiTuIZtTKdn54TqHGfNuYDDcNTjUBoeHDVbby3321sxu_GfaV1aB13sAi8XJZ4w2lL9cC1Iqphn_A9Nko9o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>233651460</pqid></control><display><type>article</type><title>Short-and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya : A Randomized Trial</title><source>Journals@OVID</source><source>MEDLINE</source><source>Free E- Journals</source><source>Journals@Ovid Complete</source><creator>SARNA, Avina ; LUCHTERS, Stanley ; GEIBEL, Scott ; CHERSICH, Matthew F ; MUNYAO, Paul ; KAAI, Susan ; MANDALIYA, Kishorchandra N ; SHIKELY, Khadija S ; TEMMERMAN, Marleen ; RUTENBERG, Naomi</creator><creatorcontrib>SARNA, Avina ; LUCHTERS, Stanley ; GEIBEL, Scott ; CHERSICH, Matthew F ; MUNYAO, Paul ; KAAI, Susan ; MANDALIYA, Kishorchandra N ; SHIKELY, Khadija S ; TEMMERMAN, Marleen ; RUTENBERG, Naomi</creatorcontrib><description>To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence.
Randomized controlled trial. SETTING AND ANALYTIC APPROACH: From September 2003 to November 2004, 234 HIV-infected adults were assigned m-DOT (24 weeks of twice weekly health center visits for nurse-observed pill ingestion, adherence support, and medication collection) or standard care. Follow-up continued until week 72. Self-reported and pill-count adherence and, secondarily, viral suppression and body mass index measures are reported. Generalized estimating equations adjusted for intraclient clustering and covariates were used.
During weeks 1-24, 9.1% (9/99) of m-DOT participants reported missing doses compared with 19.1% (20/105) of controls (P = 0.04) and 96.5% (517/571) of m-DOT pill-count measures were >or=95% compared with 86.1% (445/517) in controls [adjusted odds ratio = 4.4; 95% confidence interval (CI) = 2.6 to 7.5; P < 0.001. Adherence with m-DOT was 4.8 times greater (95% CI = 2.7 to 8.6; P < 0.001) with adjustment for depression and HIV-related hospitalization. In weeks 25-48, adherence with m-DOT (488/589) was similar to controls (507/630). Viral suppression at 48 weeks was 2.0 times (95% CI = 0.8 to 5.2; P = 0.13) as likely in m-DOT participants as controls. M-DOT patients had larger body mass index increases at 24 weeks (2.2 vs 1.4 kg/m3; P = 0.014). Viral suppression was more likely at week 48 (21/25 vs 13/22; P = 0.057) and week 72 (27/30 vs 15/23; P = 0.027) among depressed participants receiving m-DOT.
M-DOT increased adherence, most notably among depressed participants.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0b013e3181806bf1</identifier><identifier>PMID: 18645509</identifier><identifier>CODEN: JDSRET</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Antiretroviral drugs ; Antiretroviral Therapy, Highly Active ; Biological and medical sciences ; CD4 Lymphocyte Count ; Clinical trials ; Cohort Studies ; Depression ; Directly Observed Therapy ; Female ; Fundamental and applied biological sciences. Psychology ; HIV ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - virology ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Kenya ; Male ; Medical sciences ; Medical treatment ; Mental depression ; Microbiology ; Miscellaneous ; Patient Compliance ; Social Class ; Surveys and Questionnaires ; Treatment Outcome ; Viral diseases ; Viral Load ; Virology</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2008-08, Vol.48 (5), p.611-619</ispartof><rights>2008 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Aug 15, 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-ba433bcfe7957862dca0f7d387b798ba1dc023043a75883339f5cc8a0af519933</citedby><cites>FETCH-LOGICAL-c439t-ba433bcfe7957862dca0f7d387b798ba1dc023043a75883339f5cc8a0af519933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20558191$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18645509$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SARNA, Avina</creatorcontrib><creatorcontrib>LUCHTERS, Stanley</creatorcontrib><creatorcontrib>GEIBEL, Scott</creatorcontrib><creatorcontrib>CHERSICH, Matthew F</creatorcontrib><creatorcontrib>MUNYAO, Paul</creatorcontrib><creatorcontrib>KAAI, Susan</creatorcontrib><creatorcontrib>MANDALIYA, Kishorchandra N</creatorcontrib><creatorcontrib>SHIKELY, Khadija S</creatorcontrib><creatorcontrib>TEMMERMAN, Marleen</creatorcontrib><creatorcontrib>RUTENBERG, Naomi</creatorcontrib><title>Short-and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya : A Randomized Trial</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence.
Randomized controlled trial. SETTING AND ANALYTIC APPROACH: From September 2003 to November 2004, 234 HIV-infected adults were assigned m-DOT (24 weeks of twice weekly health center visits for nurse-observed pill ingestion, adherence support, and medication collection) or standard care. Follow-up continued until week 72. Self-reported and pill-count adherence and, secondarily, viral suppression and body mass index measures are reported. Generalized estimating equations adjusted for intraclient clustering and covariates were used.
During weeks 1-24, 9.1% (9/99) of m-DOT participants reported missing doses compared with 19.1% (20/105) of controls (P = 0.04) and 96.5% (517/571) of m-DOT pill-count measures were >or=95% compared with 86.1% (445/517) in controls [adjusted odds ratio = 4.4; 95% confidence interval (CI) = 2.6 to 7.5; P < 0.001. Adherence with m-DOT was 4.8 times greater (95% CI = 2.7 to 8.6; P < 0.001) with adjustment for depression and HIV-related hospitalization. In weeks 25-48, adherence with m-DOT (488/589) was similar to controls (507/630). Viral suppression at 48 weeks was 2.0 times (95% CI = 0.8 to 5.2; P = 0.13) as likely in m-DOT participants as controls. M-DOT patients had larger body mass index increases at 24 weeks (2.2 vs 1.4 kg/m3; P = 0.014). Viral suppression was more likely at week 48 (21/25 vs 13/22; P = 0.057) and week 72 (27/30 vs 15/23; P = 0.027) among depressed participants receiving m-DOT.
M-DOT increased adherence, most notably among depressed participants.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Clinical trials</subject><subject>Cohort Studies</subject><subject>Depression</subject><subject>Directly Observed Therapy</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Kenya</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Mental depression</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Patient Compliance</subject><subject>Social Class</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral Load</subject><subject>Virology</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV9vFCEUxYnR2D_6DYwhJvbJqZcBZsC3Ta3auKZR1-fJhQGlmYEKs022n16abjTpi0-Qw--cm8sh5AWDUwa6f_t1dXEKBhh3nCmmoDOePSKHTAvR9EqJx_UuW9kIxuUBOSrlCoB1Quin5ICpTkgJ-pDcfv-V8tJgHOk6xZ_NxuWZnnsfLNodTZ5-SWPwwY30fcjOLtOOXpri8k1VVnGp2pLTTcg40U12uMwuLjTEapsNFnxDP7u4Q_qOrui3OiTN4bY6Nzng9Iw88TgV93x_HpMfH843Z5-a9eXHi7PVurGC66UxKDg31rtey1517WgRfD9y1ZteK4NstNByEBx7qRTnXHtprUJAL5nWnB-Tk_vc65x-b11ZhjkU66YJo0vbMnSadwpA_Rds67dL0d4lvnoAXqVtjnWJob52kokOKiTuIZtTKdn54TqHGfNuYDDcNTjUBoeHDVbby3321sxu_GfaV1aB13sAi8XJZ4w2lL9cC1Iqphn_A9Nko9o</recordid><startdate>20080815</startdate><enddate>20080815</enddate><creator>SARNA, Avina</creator><creator>LUCHTERS, Stanley</creator><creator>GEIBEL, Scott</creator><creator>CHERSICH, Matthew F</creator><creator>MUNYAO, Paul</creator><creator>KAAI, Susan</creator><creator>MANDALIYA, Kishorchandra N</creator><creator>SHIKELY, Khadija S</creator><creator>TEMMERMAN, Marleen</creator><creator>RUTENBERG, Naomi</creator><general>Lippincott Williams & Wilkins</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20080815</creationdate><title>Short-and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya : A Randomized Trial</title><author>SARNA, Avina ; LUCHTERS, Stanley ; GEIBEL, Scott ; CHERSICH, Matthew F ; MUNYAO, Paul ; KAAI, Susan ; MANDALIYA, Kishorchandra N ; SHIKELY, Khadija S ; TEMMERMAN, Marleen ; RUTENBERG, Naomi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-ba433bcfe7957862dca0f7d387b798ba1dc023043a75883339f5cc8a0af519933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Clinical trials</topic><topic>Cohort Studies</topic><topic>Depression</topic><topic>Directly Observed Therapy</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Kenya</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Mental depression</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Patient Compliance</topic><topic>Social Class</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SARNA, Avina</creatorcontrib><creatorcontrib>LUCHTERS, Stanley</creatorcontrib><creatorcontrib>GEIBEL, Scott</creatorcontrib><creatorcontrib>CHERSICH, Matthew F</creatorcontrib><creatorcontrib>MUNYAO, Paul</creatorcontrib><creatorcontrib>KAAI, Susan</creatorcontrib><creatorcontrib>MANDALIYA, Kishorchandra N</creatorcontrib><creatorcontrib>SHIKELY, Khadija S</creatorcontrib><creatorcontrib>TEMMERMAN, Marleen</creatorcontrib><creatorcontrib>RUTENBERG, Naomi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SARNA, Avina</au><au>LUCHTERS, Stanley</au><au>GEIBEL, Scott</au><au>CHERSICH, Matthew F</au><au>MUNYAO, Paul</au><au>KAAI, Susan</au><au>MANDALIYA, Kishorchandra N</au><au>SHIKELY, Khadija S</au><au>TEMMERMAN, Marleen</au><au>RUTENBERG, Naomi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short-and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya : A Randomized Trial</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2008-08-15</date><risdate>2008</risdate><volume>48</volume><issue>5</issue><spage>611</spage><epage>619</epage><pages>611-619</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><coden>JDSRET</coden><abstract>To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence.
Randomized controlled trial. SETTING AND ANALYTIC APPROACH: From September 2003 to November 2004, 234 HIV-infected adults were assigned m-DOT (24 weeks of twice weekly health center visits for nurse-observed pill ingestion, adherence support, and medication collection) or standard care. Follow-up continued until week 72. Self-reported and pill-count adherence and, secondarily, viral suppression and body mass index measures are reported. Generalized estimating equations adjusted for intraclient clustering and covariates were used.
During weeks 1-24, 9.1% (9/99) of m-DOT participants reported missing doses compared with 19.1% (20/105) of controls (P = 0.04) and 96.5% (517/571) of m-DOT pill-count measures were >or=95% compared with 86.1% (445/517) in controls [adjusted odds ratio = 4.4; 95% confidence interval (CI) = 2.6 to 7.5; P < 0.001. Adherence with m-DOT was 4.8 times greater (95% CI = 2.7 to 8.6; P < 0.001) with adjustment for depression and HIV-related hospitalization. In weeks 25-48, adherence with m-DOT (488/589) was similar to controls (507/630). Viral suppression at 48 weeks was 2.0 times (95% CI = 0.8 to 5.2; P = 0.13) as likely in m-DOT participants as controls. M-DOT patients had larger body mass index increases at 24 weeks (2.2 vs 1.4 kg/m3; P = 0.014). Viral suppression was more likely at week 48 (21/25 vs 13/22; P = 0.057) and week 72 (27/30 vs 15/23; P = 0.027) among depressed participants receiving m-DOT.
M-DOT increased adherence, most notably among depressed participants.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>18645509</pmid><doi>10.1097/QAI.0b013e3181806bf1</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 2008-08, Vol.48 (5), p.611-619 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69368008 |
| source | Journals@OVID; MEDLINE; Free E- Journals; Journals@Ovid Complete |
| subjects | Acquired immune deficiency syndrome Adult AIDS AIDS/HIV Anti-HIV Agents - therapeutic use Antiretroviral drugs Antiretroviral Therapy, Highly Active Biological and medical sciences CD4 Lymphocyte Count Clinical trials Cohort Studies Depression Directly Observed Therapy Female Fundamental and applied biological sciences. Psychology HIV HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology Human immunodeficiency virus Human viral diseases Humans Infectious diseases Kenya Male Medical sciences Medical treatment Mental depression Microbiology Miscellaneous Patient Compliance Social Class Surveys and Questionnaires Treatment Outcome Viral diseases Viral Load Virology |
| title | Short-and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya : A Randomized Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T03%3A50%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short-and%20Long-Term%20Efficacy%20of%20Modified%20Directly%20Observed%20Antiretroviral%20Treatment%20in%20Mombasa,%20Kenya%20:%20A%20Randomized%20Trial&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=SARNA,%20Avina&rft.date=2008-08-15&rft.volume=48&rft.issue=5&rft.spage=611&rft.epage=619&rft.pages=611-619&rft.issn=1525-4135&rft.eissn=1944-7884&rft.coden=JDSRET&rft_id=info:doi/10.1097/QAI.0b013e3181806bf1&rft_dat=%3Cproquest_cross%3E1527719921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=233651460&rft_id=info:pmid/18645509&rfr_iscdi=true |